Supernus Pharmaceuticals, Inc., a biopharmaceutical company based in Rockville, Maryland, revealed on September 2, 2026, that they will take part in upcoming investor conferences in September. The company, listed on Nasdaq as SUPN, specializes in creating and distributing treatments for central nervous system (CNS) disorders. This move emphasizes their commitment to engaging with investors and stakeholders.
